Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-07-01 17:36:15 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.annonc.2026.01.009
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0923753426000189
其他信息:
出版社: Elsevier BV
作者: S.-D. Hong; Y.-S. Wang; H.-Y. Zhao; Y.-Y. Zhao; Q.-M. Wang; Y.-X. Ma; Y.-S. Li; Y. Huang; Y.-P. Yang; Z.-M. Fu; L.-K. Chen; F. Zhou; J. Yang; X.-Y. Li; X. Hou; N.-N. Zhou; L.-H. Sun; G.-F. Zhang; J.-W. Cui; L. Wu; G. Chen; Y.-X. Zhang; H.-Y. Wang; D.-Q. Lv; J.-H. Shi; B. Jiang; C. Li; X.-L. Li; K.-J. Tang; Y. Yu; Y.-H. Ji; Z.-Y. He; Y. Zhu; H. Zhu; S. Xiao; C.-C. Zhou; L. Zhang; W.-F. Fang
